Nurix Therapeutics

NRIX

Market cap $757M

Nurix Therapeutics maintains a Strong Buy rating, driven by promising progress with its oral BTK degrader bexobrutideg for relapsed/refractory CLL. NRIX plans to initiate a pivotal single-arm phase 2 study in 2H 2025, potentially enabling Accelerated Approval based on strong phase 1a data (80.9% ORR). Future expansion includes a phase 3 randomized trial and combinations to target 1st- and 2nd-line CLL, addressing a multibillion-dollar market opportunity.

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $0.67 per share a year ago.

Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025

Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Presentation of preclinical data from novel IRAK4 protein degrader, GS-6791, discovered in Nurix's ongoing research collaboration with Gilead Sciences

Nurix Therapeutics, Inc. (NASDAQ:NRIX ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 1:30 PM EDT Company Participants Arthur Sands - CEO, President & Director Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Presentation Derek Archila Senior Equity Analyst All right, everyone. I think we'll get started here with our next fireside discussion.

Nurix Therapeutics, Inc. (NASDAQ:NRIX ) Baird Global Healthcare Conference 2025 September 9, 2025 10:50 AM EDT Company Participants Arthur Sands - CEO, President & Director Conference Call Participants Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division Presentation Brian Skorney Senior Research Analyst Good morning, everyone.

Nurix Therapeutics, Inc. (NASDAQ:NRIX ) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 1:30 PM EDT Company Participants Arthur Sands - CEO, President & Director Conference Call Participants Robert Burns - H.C.

Nurix Therapeutics, Inc. (NASDAQ:NRIX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 7:00 AM EDT Company Participants Arthur Sands - CEO, President & Director Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst All right. Great. Good morning.

SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer, Hans van Houte, chief financial officer, John Northcott, chief commercial officer, and Jason Kantor, Ph.D., chief business officer, will participate in several investor conferences in September.